Marquis Who s Who Takes a Fresh Look at STEM to Recognize American Influencers and Innovators for the May Installment of the Maker s List
Marquis also recognizes Asian American and Pacific Island Americans of influence in celebration of AAPI Heritage Month
News provided by
Share this article
Share this article
UNIONDALE, N.Y., May 3, 2021 /PRNewswire/ Marquis Who s Who (MWW), the world s leading biographical publisher, has released the May edition of the Maker s List to recognize
Influencers and
Innovators in STEM. For this month s list, MWW has reimagined the traditional definition of STEM to highlight Science, Technology, Education and Medicine. The Maker s List features some of the most influential individuals in their respective fields, selected from thousands of professionals across the country. Spearheaded by
India continues to shatter its own world records in newly reported COVID-19 cases, while thousands die each day amid the world’s worst outbreak of the coronavirus. On Friday the U.S. announced that it would restrict travel from the country.
India blames a virus variant as its Covid crisis deepens
SECTIONS
India blames a virus variant as its Covid crisis deepensBy Jeffrey Gettleman, Shalini Venugopal and Apoorva Mandavilli, Bloomberg
Last Updated: Apr 30, 2021, 10:52 AM IST
Share
Synopsis
As supplies run dangerously low and hospitals are forced to turn away the sick, scientists are trying to determine what role variants of the virus might be playing. They are working with precious little data. India, like many other countries, has not built up a robust system to track viruses.
Officials in India are trying to track how many fully vaccinated people have fallen ill, a measure called the breakthrough infection rate.
Biotechnology Company Centivax Officially Launches
News provided by
Share this article
Share this article
SAN FRANCISCO, April 29, 2021 /PRNewswire/ Centivax Inc. is proud to announce its launch on Jan. 1, 2021, as a fully independent biotechnology company developing broad-spectrum therapeutics and a vaccines portfolio, including indications in COVID-19, multi-drug resistant bacteria, influenza, antivenom and oncology. Our unusually mature portfolio of fully owned Centivax assets has been made possible by advanced computational immunoengineering technology platforms and intellectual property that enable Centivax to rapidly create the broad-spectrum antibodies and broad-spectrum vaccines clearly needed in 21st-century medicine, says Dr. Jacob Glanville, Founder and CEO of Centivax. It is these platforms that enable Centivax to enter clinical development of our first therapeutic within eight months of launch.